COPD treatment: triple vs. double inhaler for air trapping
Part of Lungs & breathing clinical trials.
This trial tests whether adding a third medicine (fluticasone furoate/vilanterol/umeclidinium) to a two-medicine inhaler (vilanterol/umeclidinium) can reduce air trapping and inflammation in the lungs and blood of people with COPD GOLD B. It may help you breathe better and have fewer symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have COPD GOLD B (a stage where you have mild symptoms but a higher risk of flare-ups).
- You have had no more than 1 COPD flare-up in the past year.
- You are currently using a long-acting bronchodilator (LAMA or LAMA/LABA) or a short-acting bronchodilator.
- You are not currently taking a triple therapy inhaler (steroid + two bronchodilators).
- You do not have other serious lung conditions like tuberculosis, lung cancer, bronchiectasis, or lung fibrosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether using one or more inhalers, together with a smartphone app, can help people manage chronic obstructive pulmonary disease (COPD) better. You may be eligible if you have COPD, need “triple therapy” (three medicine types), and can use the app and surveys.
This trial tests a once-daily inhaler that combines a long-acting bronchodilator with a corticosteroid to see if it improves breathing, lung function, and quality of life in people with moderate-to-severe COPD who have significant shortness of breath.
This trial is testing a combination of three inhaled medicines (triple therapy) to see how well they help the small airways in people whose lung disease is caused by breathing in smoke from cooking or heating with wood or other biomass fuels. It may be a good fit if you have COPD or chronic bronchitis from this type of exposure.
This trial tests a new inhaler that combines three medicines (fluticasone, formoterol, and glycopyrronium) to see if it helps people with chronic obstructive pulmonary disease (COPD) breathe better and have fewer flare-ups. It may be an option if you have COPD and are looking for a convenient once- or twice-daily treatment.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This study uses a special MRI scan to see how well a single triple inhaler works for people with COPD who have moderate to severe shortness of breath or feel their health is not good. It compares two groups: those with a low risk of flare-ups and those with a high risk, to find out if the treatment helps both groups.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.